Results 111 to 120 of about 27,181 (240)

Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease

open access: yesInfection and Drug Resistance, 2014
Carine P Hedari,* Rima W Khinkarly,* Ghassan S Dbaibo Center for Infectious Diseases Research, Division of Pediatric Infectious Diseases, Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon ...
Hedari CP, Khinkarly RW, Dbaibo GS
doaj  

Strategic evaluations and techno-economic networks. Vaccine innovation in the Cuban biotech sector: for public health – or for profits? [PDF]

open access: yes
In this paper the Cuban biotech sector with its highly integrated vaccine industry is analyzed in the perspective of the techno-economic network model of Michel Callon. The paper discusses the strategic evaluations that have been performed in the sector.
Jens Plahte
core  

EPI Update, March 25, 2011 [PDF]

open access: yes, 2011
Weekly newsletter for Center For Acute Disease Epidemiology of Iowa Department of Public ...

core  

A Re-assessment of 4CMenB Vaccine Effectiveness Against Serogroup B Invasive Meningococcal Disease in England based on an Incidence Model [PDF]

open access: green, 2021
Lorenzo Argante   +4 more
openalex   +1 more source

Meningococcal conjugate vaccines: optimizing global impact

open access: yesInfection and Drug Resistance, 2011
Andrew Terranella1,2, Amanda Cohn2, Thomas Clark2 1Epidemic Intelligence Service, Division of Applied Sciences, Scientific Education and Professional Development Program Office, 2Meningitis and Vaccine Preventable Diseases Branch, National Center for ...
Terranella A, Cohn A, Clark T
doaj  

Immunogenicity and safety of meningococcal vaccines, MenACWY-CRM and 4CMenB, in groups at increased risk for meningococcal disease

open access: yesExpert Review of Vaccines
Introduction Individuals with immunocompromising conditions (e.g. asplenia, complement deficiency, HIV infection) or with high exposure to Neisseria meningitidis (e.g.
Shravani Bobde   +3 more
doaj   +1 more source

Meningococcal disease. Meningococcal conjugate polysaccharide vaccines and new generation vaccines. Report 3

open access: yesБиопрепараты: Профилактика, диагностика, лечение, 2018
Despite the progress in fighting against infectious diseases of bacterial origin, the incidence of generalized forms of meningococcal infection (GFMI) remains a topical public health problem not only in countries with historical high incidence, but also ...
M. V. Abramtseva   +2 more
doaj  

Efficacy and Safety of Quadrivalent Conjugate Meningococcal Vaccines: A Systematic Review and Meta-Analysis. [PDF]

open access: yesVaccines (Basel), 2023
Conti A   +5 more
europepmc   +1 more source

Impact of meningococcal group B OMV vaccines, beyond their brief

open access: yesHuman Vaccines & Immunotherapeutics, 2018
Meningococcal group B outer membrane vesicle vaccines have been used widely in Cuba, New Zealand, and Brazil. They are immunogenic and initially assessed largely by their ability to induce serum bactericidal activity.
Helen Petousis-Harris
doaj   +1 more source

Home - About - Disclaimer - Privacy